View Single Post
Old 05-10-2008, 02:51 PM
mrsD's Avatar
mrsD mrsD is offline
Wisest Elder Ever
 
Join Date: Aug 2006
Location: Great Lakes
Posts: 33,508
15 yr Member
mrsD mrsD is offline
Wisest Elder Ever
mrsD's Avatar
 
Join Date: Aug 2006
Location: Great Lakes
Posts: 33,508
15 yr Member
Lightbulb Mel...

Once people are on medications, for diabetes, r-lipoic acid has to be used
very carefully. It will lower blood sugar, and perhaps then your medications would need to be adjusted.

In your particular case, you are in that ACCORD study....don't they have rules
that you cannot take things that interfere with the blood sugar?
Most of the time studies are very strict and restrictive.

You should ask your doctors there if it is allowed.

The benefits of course of r-lipoic on the PN itself have been published for quite a while now. (as alpha lipoic acid). R-lipoic just requires much lower doses.

Here is a new paper from Russia in fact:
Quote:
1: Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(2):27-30.Links
[Implication of alpha-lipoic acid preparations in the treatment of diabetic neuropathy.]
[Article in Russian]

Al'-Zamil' MK, Brezhneva EV.

Twenty-eight patients, 17 women and 11 men, aged 40-70 years, with distal sensory-motor diabetic neuropathy of the lower extremities were treated with berlition, an alpha-lipoic acid preparation, in dosage 600 mg daily during 3 months. The treatment resulted in the significant reduction of clinical (sensory and motor) and neurological changes of lower extremity peripheral nerves.

PMID: 18427500 [PubMed - as supplied by publisher]
and here is an interesting paper... switching patients from alpha lipoic acid
to more costly less useful drugs..
Quote:
1: J Diabetes Complications. 2008 Apr 8 [Epub ahead of print]Click here to read Links
Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients.
Ruessmann HJ; on behalf of the German Society of out patient diabetes centres AND (Arbeitsgemeinschaft niedergelassener diabetologisch tätiger Ärzte e.V.).

Heinz-Jürgen Ruessmann, President AND, Wilhelminenstr. 22, 46537 Dinslaken, Germany.

In this retrospective real-world study, we aimed to evaluate whether switching from the pathogenetic treatment option alpha-lipoic acid to drugs for symptomatic treatment of neuropathic pain such as gabapentin would be associated with changes in efficacy, safety, and cost-effectiveness. A cohort of 443 diabetic patients with chronic painful neuropathy were treated with alpha-lipoic acid 600 mg qd orally for a mean period of 5 years. After stopping this treatment, 293 patients were switched to gabapentin (600-2400 mg/day), while 150 patients remained untreated because of no acute symptoms. In the untreated group, 110 (73%) patients developed neuropathic symptoms as soon as 2 weeks after the end of treatment with alpha-lipoic acid. In the group started on gabapentin, 131 (45%) patients had to stop taking the drug due to intolerable side effects. Among the patients treated with gabapentin 132 (45%) were responders on an average dose of 1200 mg/day, whereas 161 (55%) were nonresponders at gabapentin doses up to 2400 mg/day. These patients required an alternative treatment which consisted of pregabalin, carbamazepine, amitriptyline, tramadol, or morphine as monotherapy or in combination. The daily costs for alpha-lipoic acid were considerably lower than those for gabapentin or several frequently used drug combinations. The frequency of outpatient visits was 3.8 times per 3 months during the treatment period with alpha-lipoic acid, while it increased to 7.9 per 3 months after switching to gabapentin or the other pain medications. In conclusion, switching from long-term treatment with alpha-lipoic acid to central analgesic drugs such as gabapentin in painful diabetic neuropathy was associated with considerably higher rates of side effects, frequencies of outpatient visits, and daily costs of treatment. The pathogenic treatment option represents for the practicing diabetologist an effective, safe, and cost-effective treatment option for the majority of patients with diabetic polyneuropathy.

PMID: 18403218 [PubMed - as supplied by publisher]
__________________
All truths are easy to understand once they are discovered; the point is to discover them.-- Galileo Galilei

************************************

.
Weezie looking at petunias 8.25.2017


****************************
These forums are for mutual support and information sharing only. The forums are not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Always consult your doctor before trying anything you read here.
mrsD is offline   Reply With QuoteReply With Quote